Quick Answer
Exousia Bio, Inc. reported Operating Income Loss of -$56.4 thousand for the year ending 2023.
- This data is from Exousia Bio, Inc.'s annual report (Form 10-K), filed with the SEC on September 1, 2023.
- XBRL data for this metric is available from 2023 to 2023 (1 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2022: -$937.00 | Q3 2022: -$13.0 thousand | Q4 2022: -$8.4 thousand | Q1 2023: -$8.3 thousand | Q3 2023: -$12.2 thousand | Q4 2023: -$7.4 thousand | Q1 2024: -$8.7 thousand | Q3 2024: -$4.3 thousand | Q4 2024: $7.0 thousand | Q3 2025: -$31.8 thousand | Q4 2025: -$237.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: